Deep dives on the conditions, lab markers, and clinical decisions that define modern primary care — written the way a provider thinks, in language anyone can use.
Standard lipid panels miss nearly half of patients destined for a cardiac event. ApoB, Lp(a), fasting insulin, and HOMA-IR can reveal metabolic dysfunction years before traditional markers become abnormal.
The 2026 ACC/AHA guidelines now recommend universal Lp(a) screening as a Class 1 recommendation. One test, lifetime implications, and most patients have never heard of it.
LDL-C measures the cholesterol content of particles. ApoB counts the particles themselves. For small dense LDL and VLDL, that distinction is the difference between catching risk and missing it entirely.
The ACC/AHA replaced the Pooled Cohort Equations with PREVENT — incorporating kidney function, metabolic factors, and social determinants. Here's what changed and why it matters for your patients.
Two newer pharmacologic options now occupy the 2026 guidelines. What they do, who they're for, and how they fit alongside statins and ezetimibe in a modern dyslipidemia management strategy.
Fasting glucose often stays normal for years into insulin resistance. HOMA-IR calculation from fasting insulin is the upstream screening tool that changes the conversation entirely.
HOMA-IR above 2.0 signals insulin resistance. Above 2.9 signals significant resistance. The math is simple; the clinical implications are not. A plain-language explainer with actionable guidance.
Visceral adiposity drives systemic inflammation, hepatic insulin resistance, and cardiovascular risk independently of BMI. What to measure, and what to do when the numbers are elevated.
HbA1c reflects average blood glucose over 90 days — after the metabolic damage has begun. Adding fasting insulin to your annual labs can detect risk 5–10 years earlier at no significant cost.
Subclinical hypothyroidism frequently presents with a normal TSH. A complete workup includes Anti-TPO, Anti-TgAb, Free T3, Free T4, and ultrasound when clinically indicated.
Anti-TPO and anti-thyroglobulin antibodies confirm autoimmune thyroid disease — but elevated antibodies alone don't always require treatment. Understanding the clinical picture separates monitoring from intervention.
TI-RADS categorizes thyroid nodules by malignancy risk — from TR1 (benign) to TR5 (high suspicion). A clinical guide to ordering, interpreting, and communicating ultrasound findings to patients.
Reference ranges are population averages, not optimal targets. This guide walks through a standard CMP, CBC, and lipid panel — explaining what each marker actually means, not just whether it's flagged.
Iron deficiency, anemia of chronic disease, B12 deficiency, and hemolysis can all lower hemoglobin — and each requires a completely different workup. Profile A vs. Profile B, explained clinically.
A GFR of 58 in a 30-year-old is very different from the same number in a 75-year-old. Context, trajectory, and the creatinine-to-BUN ratio matter more than any single result in isolation.
USPSTF guidelines, ACC/AHA recommendations, and the clinical logic behind scheduling colonoscopies, mammograms, DEXA scans, and cardiac risk assessments — organized by decade of life.
What separates chronically healthy patients from chronically ill ones at 70 is rarely luck. It's specific, measurable behaviors and biomarker patterns that appear two to three decades earlier.
Office blood pressure measurements miss up to 30% of patients with true hypertension and falsely flag others who are normal. Ambulatory and home monitoring protocols, explained with clinical thresholds.
Check back soon — new content is added regularly. Or submit a topic request.